Navidea Biopharmaceuticals' NAV4694 β-Amyloid Imaging Agent to Be Used in Alzheimer's Disease Studies by Australian Imaging

Navidea Biopharmaceuticals, Inc. (NYSE: NAVB ), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL) plans to switch to using Navidea's Fluorine-18 labeled β-amyloid imaging candidate, NAV4694, from 11C-labeled Pittsburgh Compound-B (PiB) for its comprehensive research